Quantcast
Last updated on April 16, 2014 at 11:25 EDT

Latest Vanda Pharmaceuticals Inc. Stories

2013-01-22 08:29:37

WASHINGTON, Jan. 22, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the fourth quarter of 2012 on Tuesday, February 12, 2013, before the market opens. The Company will host a conference call at 10:00 AM ET on Tuesday, February 12, 2013, during which Vanda management will discuss...

2012-12-18 08:27:18

WASHINGTON, Dec. 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced positive results from the SET (Safety and Efficacy of Tasimelteon) Phase III study, evaluating tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24). Tasimelteon succeeded in the primary endpoint of Entrainment of the melatonin (aMT6s) rhythm as compared to placebo. Additionally, tasimelteon demonstrated significant improvements across a number of sleep and...

2012-12-13 20:21:32

WASHINGTON, Dec. 13, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), announced today that the European Medicines Agency's (EMA) Committee for Medicinal Product for Human Use (CHMP) has issued a negative opinion recommending against approval of Fanaptum(TM) (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum(TM) did not outweigh its risks and recommended against...

2012-11-07 08:27:12

WASHINGTON, Nov. 7, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2012. Key Highlights: The tasimelteon Non-24-Hour Disorder (Non-24) program continues towards the goal of a projected mid-2013 New Drug Application...

2012-11-05 20:23:35

WASHINGTON, Nov. 5, 2012 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the Lazard Healthcare Conference in New York City on Wednesday, November 14, 2012 at 3:00 p.m. Eastern Time. The presentation at the Lazard Healthcare Conference will be webcast live on...

2012-10-17 19:21:05

WASHINGTON, Oct. 17, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the third quarter of 2012 on Wednesday, November 7, 2012, before the market opens. The Company will host a conference call at 10:00 AM ET on Wednesday, November 7, 2012, during which Vanda management will discuss...

2012-10-15 07:28:36

WASHINGTON, Oct. 15, 2012 /PRNewswire/ -- Vanda Pharmaceuticals (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, reported today that tasimelteon has been shown for the first time to restore daily cortisol rhythms in totally blind patients suffering from Non-24-Hour Disorder (Non-24). Tasimelteon was previously reported to entrain the 24-hour rhythm of melatonin secretion in...

2012-08-23 14:22:19

WASHINGTON, Aug. 23, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will present at two upcoming healthcare investor conferences during September 2012. Vanda will present at the Stifel Nicolaus 2012 Healthcare Conference, being held in Boston, Massachusetts, on Wednesday September 5, 2012 at 4:25 p.m....

2012-08-09 02:28:49

WASHINGTON, Aug. 9, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that the Israeli Ministry of Health (MoH) has granted market approval for Fanapt(TM) for the treatment of schizophrenia. Vanda will commercialize Fanapt(TM) in Israel through its partner Megapharm Ltd. About Megapharm Megapharm Ltd....

2012-08-02 02:30:35

WASHINGTON, Aug. 2, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2012. Key Highlights: The tasimelteon Non-24-Hour Disorder (Non-24) program continues to advance towards the goal of a projected mid-2013 New Drug...